Recent advances in dermatology (Q34503639)

2 August 2017

1 reference

title

Recent advances in dermatology. (English)

1 reference

2 August 2017

Sandra Jones Wu

1

1 reference

2 August 2017

Artthapol Tanphaichitr

series ordinal

2

1 reference

2 August 2017

Micki Ly

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Clinics in podiatric medicine and surgery

2 August 2017

published in

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

65-78

1 reference

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Imiquimod: an immune response modifier

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Imiquimod in clinical practice

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Ciclopirox nail lacquer solution 8% in the 21st century

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Cellular and immunologic mechanisms in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

"Topical immunomodulators?": introducing old friends and a new ally, tacrolimus

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Anti‐inflammatory activity of antifungal preparations

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Immunomodulatory and pharmacologic properties of imiquimod

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016/S0891-8422(03)50081-8

7 January 2021

10.1016/S0891-8422(03)00081-8

Identifiers

DOI

1 reference

2 August 2017

1 reference